WAT Waters Corporation
Great chromatography franchise, but even normalized post-BD margins struggle to justify the price.
The story
Waters is a best-in-class franchise in LC/MS chromatography with a large installed base, and roughly half its revenue comes from recurring consumables and service. The BD Biosciences and Diagnostics combination roughly doubles revenue and adds flow cytometry and diagnostics. TTM GAAP figures are distorted by partial-period consolidation, deal costs and acquired-intangible amortization. Underneath, this is a mature, cash-generative business: mid-single-digit organic growth, plus cost synergies that should lift blended margins back toward Waters' historical levels.
Y1 growth moves up from 25% to 30% because TTM revenue of 4.64B still captures only part of BD's year; a full year of the combined company runs near 6.5B. Target margin rises from 26% to 28%: legacy Waters ran 28-30%, BD's lower margins are partly offset by about $345M of targeted cost synergies, and the non-cash amortization of acquired intangibles should not be capitalized into steady-state economics. Sales-to-capital rises from 1.5 to 1.8 because the reported 1.17 is inflated by merger goodwill, while organic growth needs little incremental capital (capex is 0.15B against 0.61B of D&A). Beta, terminal growth and horizon are unchanged.
Value drivers
| Revenue growth (Y1) | 30.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 28.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.80 |
| Beta | 1.00 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.3% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 8.15B |
| PV of terminal value | 20.36B |
| Equity value | 27.13B |
| ÷ shares → per share | $276.33 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 6.04B | 30.0% | 12.7% | 653.80M | 774.04M | -120.25M | -110.00M |
| 2 | 7.62B | 26.2% | 17.8% | 1.16B | 879.27M | 276.31M | 231.22M |
| 3 | 9.33B | 22.4% | 22.9% | 1.82B | 949.50M | 869.77M | 665.80M |
| 4 | 11.07B | 18.6% | 28.0% | 2.64B | 966.25M | 1.67B | 1.17B |
| 5 | 12.71B | 14.9% | 28.0% | 3.03B | 913.60M | 2.12B | 1.36B |
| 6 | 14.12B | 11.1% | 28.0% | 3.37B | 781.95M | 2.58B | 1.51B |
| 7 | 15.15B | 7.3% | 28.0% | 3.61B | 571.55M | 3.04B | 1.63B |
| 8 | 15.68B | 3.5% | 28.0% | 3.74B | 294.57M | 3.44B | 1.69B |
Key risks
- BD integration slippage or synergy shortfall leaves blended margins stuck in the low 20s
- Pharma and biotech capex cycles, plus China and tariff exposure, weigh on instrument replacement demand
- Higher leverage and acquired diagnostics businesses with weaker growth dilute the franchise's quality
Catalysts
- Quarterly prints showing synergy capture and GAAP margins recovering toward the high 20s
- LC instrument replacement cycle and GLP-1/biologics QA/QC demand driving consumables growth